ClinicalTrials.gg
CompletedNCT07134907Updated Aug 21, 2025

The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH

A Phase 4 interventional study of Silodosin and Tamsolusin in BPH (Benign Prostatic Hyperplasia), sponsored by Shanghai Huilun Pharmaceutical Co., Ltd.. Completed at 6 sites in China. Open to male participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by Shanghai Huilun Pharmaceutical Co., Ltd. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Jul 2022, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing silodosin in Prostatic Hyperplasia — 4 open to participants now, 4 under way, none of them phase 3. silodosin · Prostatic Hyperplasia.

Enrollment
14th of 19
110 · median 141
Started
2022
with 1 other
Phase 4
11 of 19
4 open now
Registered
15th of 19
by date
Lead sponsor
1 of 19
Shanghai Huilun Pharmaceutical Co., Ltd.

Among the 19 studies testing silodosin in Prostatic Hyperplasia, this one is the 14th largest by enrollment, is one of 2 that started in 2022, is one of 11 in phase 4, and was the 15th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

4 of the 19 studies testing silodosin in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About silodosin

silodosin: first FDA approval 2008 (RAPAFLO), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 60 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing silodosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if Qianweitai (QWT, silodosin capsule) works to treat BPH/LUTS in male adults. It will also learn the safety about QWT. The main questions it aims to answer are:

  1. Whether QWT is non inferior to tamsulosin in the reduction of IPSS total score?
  2. Dose QWT have other advantages in the improvement of LUTS?

Participants will:

  1. Orally take QWT twice daily or tamsulosin once daily for 12 weeks.
  2. Visit the clinic at week 1、 2、4、8 and 12 for checkups and tests.
Read the detailed description

This trial is designed as two stages: screening period, treatment and follow-up period.

Screening period (days -28 to 0): After signing the informed consent form, the subjects entered into the screening period, and made a 24-hour urination diary and screening examination.

Treatment and Follow-up period: eligible patients were randomly assigned to 2 groups according to 1: 1 and received Tamsulosin or Silodosin or for 12 weeks. During the treatment period, the subjects' diaries were recorded according to the requirements of the scheme, and they were followed up at 1 week (7±2 days), 2 weeks (14±3), 4 weeks (28±5 days), 8 weeks (56±7 days) and 12 weeks (84±10 days). During the visit, relevant scale scores and laboratory examinations were performed, and the occurrence of adverse events during the follow-up was recorded to evaluate the safety.

03

Conditions studied

  • BPH (Benign Prostatic Hyperplasia)

Keywords

  • Benign Prostatic Hyperplasia
  • Qianweitai
  • Tamsulosin
  • Lower Urinary Tract Symptoms
04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male Subjects aged 60 ~ 80 years, clinically diagnosed as benign prostatic hyperplasia.
  2. Has an IPSS score ≥ 8 points at Screening and Baseline.
  3. Has a 4 ≤ Qmax ≤ 15 ml/s when urination volume > 150 ml.
  4. Has a prostate volume (PV) ≥ 30 ml by ultrasound examination.
  5. Subjects who can read, understand, and complete the research questionnaire.
  6. Subjects willing to participate voluntarily in this clinical trial, give and sign informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with prostate cancer or other malignant tumors.
  2. Subjects have serum tPSA > 10ng/ml, or 4 ≤ tPSA ≤ 10ng/ml while fPSA/tPSA \< 0.16 times.
  3. Subjects suffered from other diseases causing dysuria, such as bladder neck spasm, urethral stricture, neurogenic bladder dysfunction, etc.
  4. Subjects have suffered from acute urinary retention, or complicated with gross hematuria, urinary tract infection, bladder stones, secondary upper urinary tract hydronephrosis, urinary incontinence, renal insufficiency and other Subjects that researchers believe meet the surgical indications.
  5. Subjects have undergone prostate surgery, microwave therapy, urethral dilatation or acute urinary retention catheterization or other invasive procedures.
  6. Subjects have residual urine volume (PVR) > 100ml, or those who may have urinary retention and need catheterization.
  7. Subjects who took α receptor blockers, traditional Chinese medicine or botanical drugs for treating BPH within two weeks before participating this clinical trial.
  8. Subjects who take 5α reductase inhibitor or other antiandrogen therapy drugs within half a year before participating this clinical trial.
  9. Subjects who need to take drugs prohibited in this study or adopt prohibited treatment methods during treatment.
  10. Subjects who Complicated with severe cardiovascular and cerebrovascular diseases, respiratory diseases, blood diseases, liver and kidney diseases.
  11. There are significant abnormalities in clinical or laboratory examination indexes of patients, such as and AST ≥ 2.5 times of the upper limit of reference value, creatinine (Scr) > 1.5 times of the upper limit of reference value, or poor blood glucose control (fasting blood glucose FPG ≥ 10 mmol/L).
  12. Subjects who are allergic to the drugs or ingredients used in the test definitely.
  13. Any otherSubjects in the opinion of researchers is not suitable for inclusion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Qianweitai

    Patients orally take Qianweitai (silodosin capsule), 4mg/capsule, 1 capsule/time, bid, after breakfast and dinner).

    Drug: Silodosin

  • Active comparator
    Tamsulosin

    Patients orally take tamsulosin hydrochloride capsules (1 tablet each time, once daily).

    Drug: Tamsolusin

Interventions

  • Silodosin is an α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieve the dynamic obstruction of bladder outlet, and improve the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule,1 capsule/time, bid, after breakfast and dinner.

    Also known as: Qianweitai

  • Tamsulosin is an α1A-adrenergic receptor blocker which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.

    Also known as: Harnal

06

What researchers measure

Primary outcomes

  1. International Prostate Symptom Score(IPSS)

    Changes of IPSS scores at the 12th week of treatment compared with baseline scores.

    Time frame: week 12

Secondary outcomes

  1. International Prostate Symptom Score(IPSS) total score

    Changes of IPSS scores at 1, 2, 4 and 8 weeks after treatment compared with baseline

    Time frame: 1, 2, 4 and 8 weeks

  2. IPSS storage subscore

    Changes of IPSS storage subscore at 1, 2, 4 and 8 weeks after treatment compared with baseline

    Time frame: 1, 2, 4 and 8 weeks

  3. IPSS voiding subscore

    Changes of IPSS voiding subscore at 1, 2, 4 and 8 weeks after treatment compared with baseline

    Time frame: 1, 2, 4 and 8 weeks

  4. IPSS total score severity

    Proportion of patients with IPSS total score severity decreased by at least one grade at 12 weeks. The scores of the scale were divided into three grades: mild (0-7), moderate (8-19) and severe (20-35).

    Time frame: week 12

  5. Quality of life (QoL) score

    Changes in scores at 4, 8 and 12 weeks of treatment compared with baseline.The scores of the scale ranged from 0 to 6. The higher the score, the more severe the symptoms are.

    Time frame: 4, 8 and 12 weeks

  6. Maximum urinary flow rate (Qmax)

    The change of Qmax at the 12th week of treatment compared with baseline.

    Time frame: week 12

  7. Residual urine volume (PVR)

    The change of PVR at the 12th week of treatment compared with baseline.

    Time frame: week 12

  8. Prostate specific antigen (PSA)

    The change of PSA at the 12th week of treatment compared with baseline.

    Time frame: week 12

  9. Prostate volume (PV)

    Changes of PV at 12 the 12th week of treatment compared with baseline.

    Time frame: week 12

  10. Responder rate

    Responder rate is defined as the proportion of patients whose IPSS total score decreased by ≥ 25% and Qmax increased by ≥ 30% compared with baseline value after treatment.

    Time frame: week 12

  11. Proportion of patients with BPH clinical progression

    Clinical progress is defined as the first occurrence of one of the following two conditions during the trial: 1. Acute urinary retention (AUR); 2. Clinical diagnosis requires surgical treatment of BPH.

    Time frame: week 12

07

Study locations

6 sites
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
  • Wuhan Center Hospital
    Wuhan, Hubei, China
  • Wuhan No.1 Hospital
    Wuhan, Hubei, China
  • The Second Affiliated Hospital of Suzhou University
    Suzhou, Jiangsu, China
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, China
  • Ciivil Aviation General Hospital
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jul 2024, 23 months.

Of 28 phase 4 interventional studies under Prostatic Hyperplasia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 21, 2025
StartActual
Jul 18, 2022
Primary completionActual
Jul 9, 2024
CompletionActual
Jul 9, 2024
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07134907
Lead sponsor
Shanghai Huilun Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Jul 18, 2022
Primary completion
Jul 9, 2024
Completion
Jul 9, 2024
Last update
Aug 21, 2025

Study contacts

Shan Chen
principal investigator · Beijing Tongren Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silodosin

Start the discussion